Cx Precision Medicine
Developer of blood-based, proteomics-driven diagnostic tests for neurodegenerative disorders. Uses large-scale protein measurement from blood samples combined with machine learning algorithms trained on thousands of samples to produce predictive tests intended to support primary care decision-making for patients (primarily age 60+) with memory or neuromuscular complaints. Maintains an active publication record in proteomic biomarker research and is developing a pipeline of diagnostics including memory and Parkinson’s-focused assays.
Industries
Nr. of Employees
small (1-50)
Cx Precision Medicine
Products
NeuroFirst Memory (blood test)
A blood-based test intended to aid primary care assessment of memory complaints in individuals aged 60 and older by helping to rule out or identify patients who should receive further neurological evaluation for Alzheimer’s disease.
NeuroFirst Parkinson's (coming soon)
Planned blood-based test designed to help primary care physicians identify patients with motor or neuromuscular symptoms who are unlikely to have Parkinson’s disease and who do or do not require further specialist evaluation.
NeuroFirst Therapeutics Matching Test
Test concept intended to match patient biomarker profiles with potential therapeutic interventions.
NeuroFirst™
NeuroFirst™ Memory is a simple blood test that helps primary care physicians distinguish Alzheimer's-related memory issues from other non-AD causes by ruling out Alzheimer's Dementia and some other dementias. It combines proteomics biomarkers with AI machine learning algorithms to analyze a large number of proteins in blood, providing a non-invasive diagnostic tool.
NeuroFirst™ Parkinson’s
A simple blood test that helps primary care physicians identify patients who should be further evaluated for Parkinson’s Disease by ruling out Parkinson’s in patients with neuromuscular concerns such as motor/gait issues or tremors.
Lewy Body Dementia Rule-Out
A diagnostic test in development by Cx Precision Medicine to rule out Lewy Body Dementia.
NeuroFirst Memory (blood test)
A blood-based test intended to aid primary care assessment of memory complaints in individuals aged 60 and older by helping to rule out or identify patients who should receive further neurological evaluation for Alzheimer’s disease.
NeuroFirst Parkinson's (coming soon)
Planned blood-based test designed to help primary care physicians identify patients with motor or neuromuscular symptoms who are unlikely to have Parkinson’s disease and who do or do not require further specialist evaluation.
NeuroFirst Therapeutics Matching Test
Test concept intended to match patient biomarker profiles with potential therapeutic interventions.
NeuroFirst™
NeuroFirst™ Memory is a simple blood test that helps primary care physicians distinguish Alzheimer's-related memory issues from other non-AD causes by ruling out Alzheimer's Dementia and some other dementias. It combines proteomics biomarkers with AI machine learning algorithms to analyze a large number of proteins in blood, providing a non-invasive diagnostic tool.
NeuroFirst™ Parkinson’s
A simple blood test that helps primary care physicians identify patients who should be further evaluated for Parkinson’s Disease by ruling out Parkinson’s in patients with neuromuscular concerns such as motor/gait issues or tremors.
Lewy Body Dementia Rule-Out
A diagnostic test in development by Cx Precision Medicine to rule out Lewy Body Dementia.
Expertise Areas
- Blood-based diagnostics for neurodegenerative disease
- Proteomics and biomarker discovery
- Machine learning for clinical diagnostics
- Clinical validation and translational research
Key Technologies
- Proteomics
- Machine learning / AI predictive algorithms
- Blood biomarker assays
- Statistical model validation
News & Updates
PDF of a Wall Street Journal article hosted on the site addressing diagnostic challenges in Alzheimer’s disease.
Press release announcing acceptance into StartUp Health’s Moonshot Community.
Peer‑reviewed publication describing plasma biomarker characterization in a diverse community cohort.
Peer‑reviewed article reporting proteomic profiles across population groups.
Company accepted into a collaborative community focused on accelerating health innovations in Alzheimer’s disease.
PDF of a Wall Street Journal article hosted on the site addressing diagnostic challenges in Alzheimer’s disease.
Press release announcing acceptance into StartUp Health’s Moonshot Community.
Peer‑reviewed publication describing plasma biomarker characterization in a diverse community cohort.
Peer‑reviewed article reporting proteomic profiles across population groups.
Company accepted into a collaborative community focused on accelerating health innovations in Alzheimer’s disease.